US FDA OKs clinical trial on stem cell
Published: 2009-10-05 06:56:00
Updated: 2009-10-05 06:56:00
CJ Cheil Jedang says the U.S. Food and Drug Administration has allowed its U.S. partner Neuralstem Inc. to start an early-stage human trial of its spinal cord stem cells in Lou Gehrig's disease, a fatal neuromuscular condition.
The trial, which will test the safety of the cells and the surgery...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
